Ronocit 500 mg / 4 ml 5's solution for injection in ampoules
- $39.20
The instruction for medical use
of Ronocit medicine
the Trade name
of Ronocit
the International unlicensed
name Tsitikolin Lekarstvennaya a form
Solution for injections of 500 mg / 4 ml or 1000 mg / 4 ml
Structure
1 ampoule of drug contains
active agent - a tsitikolin of sodium of 525 mg or 1045 mg (it is equivalent to a tsitikolin of 500 mg or 1000 mg),
excipient - water for injections.
Description
Transparent colourless liquid
Pharmacotherapeutic group
Psychostimulants and nootropic drugs.
The code of automatic telephone exchange N06BX06
the Pharmacological
Pharmacokinetics As properties tsitikolin is natural compound which contains in an organism, the classical pharmacokinetic research cannot be executed in connection with complexity of quantitative definition of an exogenous and endogenous tsitikolin. In a pharmacokinetic research with appointment in marked C 14 – a tsitikolina its almost full absorption was observed. Within 5 days after purpose of a dose with a stake less than 1% of the appointed dose were excreted.
Pharmacodynamics
Nootropic drug. Improves transfer of nervous impulses in cholinergic neurons: positively influences plasticity of neuronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage.
Ronocit is a sincaline source, increasing synthesis of acetylcholine and stimulates biosynthesis of structural (basic) phospholipids in a membrane of neurons that promotes improvement of function of membrane mechanisms, including, to functioning of ion-exchange pumps and the receptors shipped in them which modulation is a necessary condition of neurotransfer.
Ronocit softens the symptoms which are observed in a hypoxia and ischemia of a brain, including a memory impairment, emotional lability, lack of initiative, difficulties during the performing of daily actions and self-service.
Ronocit it is effective in treatment of cognitive, sensitive and motive neurologic disorders of a degenerative and vascular etiology.
Medicine does not influence breath, pulse and arterial blood pressure therefore perhaps long-term treatment.
The indication to use
- an acute period of an ischemic stroke
- the recovery period of ischemic and hemorrhagic
strokes
- a craniocereberal injury, the acute and recovery period
- cognitive disturbances in degenerative and vascular
diseases of a brain
the Route of administration and doses
Solution for intravenous and intramuscular administration.
Intravenously appoint in the form of a slow intravenous injection (within 5 minutes) or drop intravenous injection (40-60 drops a minute) in strokes and a craniocereberal injury in an acute period 1000-2000 mg daily depending on disease severity within 3-7 days with the subsequent transition to intramuscular introduction or intake. The intravenous way of introduction is more preferable, than intramuscular.
Intramusculary: 1-2 injections a day. At intramuscular introduction it is necessary to avoid repeated administration of drug to the same place.
At long disturbances of consciousness perhaps continuous use of drug from the first stages of a disease.
In a disease and Parkinson's syndromes the recommended dose of drug makes 500 mg a day during treatment for 3-4 weeks with breaks between them.
Duration of treatment depends on disease severity and is defined by the attending physician.
Side effects
- insomnia, a headache, dizziness, excitement, a tremor,
numbness in the paralyzed extremities
- nausea, a loss of appetite, change of activity of liver
enzymes
- rash, an itching of skin, an acute anaphylaxis
- feeling of heat, in some cases – short-term lowering or increase in arterial blood pressure
of the Contraindication
- raised sensitivity to drug components
- a vagotonia (prevalence of a tone of a parasympathetic part
of the autonomic nervous system)
- children's and teenage age up to 18 years.
Medicinal interactions
Tsitikolin enhances effects of L-of dihydroxyphenylalanin.
It is not necessary to appoint along with the medicines containing
Ronocit Meclofenoxatum it can be applied at the same time with styptic means, intracranial antihypertensive drugs and usual perfused liquids
Special instructions
To cerebral decompression in brain injuries it is necessary to appoint medicines, such as Mannitolum and corticosteroid drugs.
In endocrine hemorrhage it is impossible to exceed a dose of a tsitikolin in 500 mg at single use, in this case crushing of a dose is possible (100 – 200 mg 2-3 times a day).
Pregnancy and the period of a lactation
Prescribing of drug during pregnancy is possible only if the expected advantage exceeds potential risk.
When prescribing drug in the period of a lactation it is necessary to stop breastfeeding as data on discharge of a tsitikolin with female milk are absent.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence ability to control of vehicles and use of mechanisms.
Overdose
Taking into account hypotoxicity of drug the cases of overdose are not described, even in case of exceeding therapeutic dosed
the Form of release and packing
On 4 ml of drug in glass colourless ampoules.
On 5 ampoules put in blister strip packaging and together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at
a temperature not higher than 250 S. Hranit out of children's reach!
Not to apply a period of storage of 5 years after a period of storage.
Prescription status
According to the prescription
the Producer
Vekki and To. PIAM of page and. item and., Padre Mr. Semeriya St., 5.16131 Genoa, Italy for the ROTAFARM company, Great Britain.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from the consumer on quality of products (goods)
of RK, Almaty, Suyunbaya 222 St. of B
Ph. / fax: 8 (7272) 529090
of Ronocit medicine
the Trade name
of Ronocit
the International unlicensed
name Tsitikolin Lekarstvennaya a form
Solution for injections of 500 mg / 4 ml or 1000 mg / 4 ml
Structure
1 ampoule of drug contains
active agent - a tsitikolin of sodium of 525 mg or 1045 mg (it is equivalent to a tsitikolin of 500 mg or 1000 mg),
excipient - water for injections.
Description
Transparent colourless liquid
Pharmacotherapeutic group
Psychostimulants and nootropic drugs.
The code of automatic telephone exchange N06BX06
the Pharmacological
Pharmacokinetics As properties tsitikolin is natural compound which contains in an organism, the classical pharmacokinetic research cannot be executed in connection with complexity of quantitative definition of an exogenous and endogenous tsitikolin. In a pharmacokinetic research with appointment in marked C 14 – a tsitikolina its almost full absorption was observed. Within 5 days after purpose of a dose with a stake less than 1% of the appointed dose were excreted.
Pharmacodynamics
Nootropic drug. Improves transfer of nervous impulses in cholinergic neurons: positively influences plasticity of neuronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage.
Ronocit is a sincaline source, increasing synthesis of acetylcholine and stimulates biosynthesis of structural (basic) phospholipids in a membrane of neurons that promotes improvement of function of membrane mechanisms, including, to functioning of ion-exchange pumps and the receptors shipped in them which modulation is a necessary condition of neurotransfer.
Ronocit softens the symptoms which are observed in a hypoxia and ischemia of a brain, including a memory impairment, emotional lability, lack of initiative, difficulties during the performing of daily actions and self-service.
Ronocit it is effective in treatment of cognitive, sensitive and motive neurologic disorders of a degenerative and vascular etiology.
Medicine does not influence breath, pulse and arterial blood pressure therefore perhaps long-term treatment.
The indication to use
- an acute period of an ischemic stroke
- the recovery period of ischemic and hemorrhagic
strokes
- a craniocereberal injury, the acute and recovery period
- cognitive disturbances in degenerative and vascular
diseases of a brain
the Route of administration and doses
Solution for intravenous and intramuscular administration.
Intravenously appoint in the form of a slow intravenous injection (within 5 minutes) or drop intravenous injection (40-60 drops a minute) in strokes and a craniocereberal injury in an acute period 1000-2000 mg daily depending on disease severity within 3-7 days with the subsequent transition to intramuscular introduction or intake. The intravenous way of introduction is more preferable, than intramuscular.
Intramusculary: 1-2 injections a day. At intramuscular introduction it is necessary to avoid repeated administration of drug to the same place.
At long disturbances of consciousness perhaps continuous use of drug from the first stages of a disease.
In a disease and Parkinson's syndromes the recommended dose of drug makes 500 mg a day during treatment for 3-4 weeks with breaks between them.
Duration of treatment depends on disease severity and is defined by the attending physician.
Side effects
- insomnia, a headache, dizziness, excitement, a tremor,
numbness in the paralyzed extremities
- nausea, a loss of appetite, change of activity of liver
enzymes
- rash, an itching of skin, an acute anaphylaxis
- feeling of heat, in some cases – short-term lowering or increase in arterial blood pressure
of the Contraindication
- raised sensitivity to drug components
- a vagotonia (prevalence of a tone of a parasympathetic part
of the autonomic nervous system)
- children's and teenage age up to 18 years.
Medicinal interactions
Tsitikolin enhances effects of L-of dihydroxyphenylalanin.
It is not necessary to appoint along with the medicines containing
Ronocit Meclofenoxatum it can be applied at the same time with styptic means, intracranial antihypertensive drugs and usual perfused liquids
Special instructions
To cerebral decompression in brain injuries it is necessary to appoint medicines, such as Mannitolum and corticosteroid drugs.
In endocrine hemorrhage it is impossible to exceed a dose of a tsitikolin in 500 mg at single use, in this case crushing of a dose is possible (100 – 200 mg 2-3 times a day).
Pregnancy and the period of a lactation
Prescribing of drug during pregnancy is possible only if the expected advantage exceeds potential risk.
When prescribing drug in the period of a lactation it is necessary to stop breastfeeding as data on discharge of a tsitikolin with female milk are absent.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence ability to control of vehicles and use of mechanisms.
Overdose
Taking into account hypotoxicity of drug the cases of overdose are not described, even in case of exceeding therapeutic dosed
the Form of release and packing
On 4 ml of drug in glass colourless ampoules.
On 5 ampoules put in blister strip packaging and together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at
a temperature not higher than 250 S. Hranit out of children's reach!
Not to apply a period of storage of 5 years after a period of storage.
Prescription status
According to the prescription
the Producer
Vekki and To. PIAM of page and. item and., Padre Mr. Semeriya St., 5.16131 Genoa, Italy for the ROTAFARM company, Great Britain.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from the consumer on quality of products (goods)
of RK, Almaty, Suyunbaya 222 St. of B
Ph. / fax: 8 (7272) 529090
Related Products
-10%
